Vutrisiran reduces days lost to death and/or hospitalization versus placebo in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Back

ESC2025 Premium Access

Vutrisiran reduces days lost to death and/or hospitalization versus placebo in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Session: Multidisciplinary care in heart failure

Topic: Pharmacotherapy

Speaker: Doctor M. Hanna (Cleveland, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Mazen Hanna

Cleveland Clinic Main Campus, Cleveland (United States of America)

2 presentations

0 follower

6 more presentations in this session

Impact of QRS duration on drug titration and left ventricular recovery in new-onset heart failure with reduced ejection fraction

Speaker: Doctor A. Arenas Loriente (Barcelona, ES)

A decision algorithm for palliative care initiation in heart failure patients

Speaker: Doctor I. Santos (Ponta Delgada, PT)

The efficacy and safety of hydroxychloroquine in patients with chronic inflammatory cardiomyopathy after fulminant myocarditis: a multicenter randomized study of the HYPIC trial

Speaker: Doctor W. He (Wuhan, CN)

Effects of a dyadic empowerment-based heart failure management program (De-HF) on patient-reported and clinical outcomes: a double-blind randomized controlled trial

Speaker: Doctor D. Yu (Hong Kong, HK)

Efficacy of early initiation of vericiguat in acute heart failure: a prospective study

Speaker: Doctor J. Chen (Chongqing, CN)

Access the full session

Multidisciplinary care in heart failure

Speakers: Doctor M. Hanna, Doctor A. Arenas Loriente, Doctor I. Santos, Doctor W. He, Doctor D. Yu...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources